INTI / Inhibitor Therapeutics, Inc. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 (March 30,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 (March 30, 2026) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 (March 31,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 (March 31, 2026) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction o

Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome Company outlines near-term pharmacokinetic milestones, highlights amorphous formulation strategy, and announces planned global patent fili

Exhibit 99.1 Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome Company outlines near-term pharmacokinetic milestones, highlights amorphous formulation strategy, and announces planned global patent filing TAMPA, Fla., March 31, 2026 — Inhibitor Therapeutics, Inc. (OTCQB: INTI) (“Inhibitor” or the “Company”), today provided an update on i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Therapeutics, Inc.

Signature Page Follows

Exhibit 4.1 EXECUTION VERSION THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT TH

INHIBITOR THERAPEUTICS, INC. INVESTOR LOCK-UP AGREEMENT

Exhibit 10.2 EXECUTION VERSION INHIBITOR THERAPEUTICS, INC. INVESTOR LOCK-UP AGREEMENT February 19, 2026 This Investor Lock-Up Agreement (this “Agreement”) is being delivered to you in connection with an understanding by and between Investor Therapeutics, Inc., a Delaware corporation (the “Company”), and the investor named on the signature page hereto (the “Investor”). Reference is hereby made to

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 19, 2026, between Inhibitor Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 (Februa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 (February 19, 2026) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor

MASTER SERVICES AGREEMENT

Exhibit 10.1 Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. [***] indicates that information has been redacted. MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (the “Agreement”) is made and entered into as of this 21st day of October, 2025, by and between Frameshift Management, Inc. (hereinafter referred to as “

Inhibitor Therapeutics, Inc. 2025 EQUITY INCENTIVE PLAN (Adopted as of October 21, 2025)

Exhibit 10.2 Inhibitor Therapeutics, Inc. 2025 EQUITY INCENTIVE PLAN (Adopted as of October 21, 2025) 1. Purpose. The purposes of this Plan are to: (a) attract, retain, and motivate Employees, Directors, and Consultants, (b) provide additional incentives to Employees, Directors, and Consultants, and (c) promote the success of the Company’s business, by providing Employees, Directors, and Consultan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2025 (October

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2025 (October 21, 2025) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdict

LETTER

September 15, 2025 James A. McNulty Interim Chief Financial Officer Inhibitor Therapeutics, Inc. 3014 W. Palmira Avenue Suite 302 Tampa, FL 33629 Re: Inhibitor Therapeutics, Inc. Form 10-K for the Year Ended December 31, 2024 Filed March 28, 2025 File No. 001-13467 Dear James A. McNulty: We have completed our review of your filing. We remind you that the company and its management are responsible

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Ther

Inhibitor Therapeutics, Inc. 3014 W. Palmira Avenue Suite 302 Tampa, FL 33629

Inhibitor Therapeutics, Inc. 3014 W. Palmira Avenue Suite 302 Tampa, FL 33629 VIA EDGAR July 22, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Chris Edwards Re: Inhibitor Therapeutics, Inc. Form 10-K for the Year Ended December 31, 2024 Filed March 28, 2025 File No. 001-13467 L

LETTER

July 17, 2025 James A. McNulty Interim Chief Financial Officer Inhibitor Therapeutics, Inc. 3014 W. Palmira Avenue Suite 302 Tampa, FL 33629 Re: Inhibitor Therapeutics, Inc. Form 10-K for the Year Ended December 31, 2024 Filed March 28, 2025 File No. 001-13467 Dear James A. McNulty: We have reviewed your filing and have the following comment. Please respond to this letter within ten business days

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Therapeutics, Inc.

License Agreement by and between the Company and Johns Hopkins University, Dated December 12, 2023 (Portions of this exhibit have been redacted pursuant to a request for confidential treatment.)

Exhibit 10.6 JHU EXCLUSIVE LICENSE AGREEMENT CONFIDENTIAL Confidential Treatment Requested by Inhibitor Therapeutics, Inc., IRS Employer Identification No. 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** NOTE: CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO CERTAIN PORTIONS HEREOF DENOTED WITH “[***]” EXCLUSIVE LICENSE AGREEMENT Johns Hopkins University and Inhibitor Therapeutics JHU Agreement

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications.

Exhibit 99.1 Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications. Inhibitor Therapeutics, Inc. (“Inhibitor”) (OTCQB:INTI) has entered into an exclusive, worldwide licensing agreement (the “License”) with Johns Hopkins University (JHU) for their U.S Patent 8,9

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 (December 12, 2023) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor

Consulting Agreement by and among Inhibitor Therapeutics, Inc., and Dr. Elizabeth Billingsley

Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of this 20th day of July, 2023, by and between Dermapharm Consulting LLC (hereinafter referred to as “Consultant”), with an address at 157 Hamilton Road, Lancaster, PA 17603, and Inhibitor Therapeutics, Inc. (the “Company”) a Delaware corporation with offices at 4905 South Westshore Blvd., Tam

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of incorporatio

Charter of the Scientific Advisory Board, dated October 13, 2023, filed with Form 8-K dated October 13, 2023

Exhibit 3.1 INHIBITOR THERAPUTICS, INC. SCIENTIFIC ADVISORY BOARD CHARTER Adopted October 13, 2023 I. GENERAL FUNCTION The function of the Scientific Advisory Board (the “Scientific Advisory Board”) shall be to advise and make non-binding recommendations to the Board of Directors and senior management of Inhibitor Therapeutics, Inc., (the “Company”) with respect to matters relating to the business

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 (August 23, 2023) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdictio

Second Amended and Restated Bylaws of the Company, adopted July 12, 2023, as filed with Form 8-K, dated August 29, 2023

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF INHIBITOR THERAPUTICS, INC. (a Delaware Corporation) (Adopted Effective as of July 12, 2023) These Amended and Restated Bylaws of Inhibitor Therapeutics, Inc., a Delaware corporation (the “Corporation”), are adopted pursuant to Article 12 of the Corporation’s existing Bylaws (the “Original Bylaws”) and are intended to amend, restate and replace, in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Ther

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 (May 24, 2023) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of i

JOINT FILING AGREEMENT

EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the shares of Common Stock of TPB 2012, LLC and James Donovan, has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G will, unless written notice to the contrary is delivered as described below, be jointly filed on

INTI / Inhibitor Therapeutics Inc / Black Robe Capital LLC - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INHIBITOR THERAPUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720M 10 5 (CUSIP Number) James McNulty c/o Inhibitor Therapeutics, Inc. 900 West Platt St., Suite 200 Tampa, Florida 33606 (Name, Address and Tele

INTI / Inhibitor Therapeutics Inc / TPB 2012 LLC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Inhibitor Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720M 10 5 (CUSIP Number) May 5, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

JOINT FILING AGREEMENT

EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D relating to Black Robe Capital LLC and James McNulty, has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of th

INTI / Inhibitor Therapeutics Inc / Ronald E Osman Irrevocable Trust III - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Inhibitor Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720M 10 5 (CUSIP Number) May 5, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

JOINT FILING AGREEMENT

EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Ronald E Osman Trust III and Ronald E. Osman, has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of ea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Therapeutics, Inc.

Employment Agreement by and between the Company and Francis E. O’Donnell, dated December 13, 2022, as filed with Form 8-K, dated December 19, 2022

Exhibit 10.3 INHIBITOR THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into as of December 13, 2022 (the ?Effective Date?), is made by and between Inhibitor Therapeutics, Inc., a Delaware corporation (the ?Company?) and Francis E. O?Donnell (?Executive? and, together with the Company, the ?Parties?). WHEREAS, the Company desires to assure itself of the

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 ( December 13, 2022 ) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other juris

Stipulation and Agreement of Compromise, Settlement, and Release, dated September 9, 2022, as filed with Form 8-K, dated December 19, 2022

Exhibit 10.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE HEDGEPATH, LLC, Plaintiff, v. C.A. No. 2019-0529-JTL BRENDAN MAGRAB, STEFAN J. CROSS, DR. R. DANA ONO, ROBERT D. MARTIN, W. MARK WATSON, NICHOLAS J. VIRCA and MAYNE PHARMA VENTURES PTY LTD., Defendants, and HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation, Nominal Defendant. SAMUEL SEARS, Individually And On Behalf of All Others

Employment Agreement by and between the Company and James A. McNulty, dated December 13, 2022, as filed with Form 8-K, dated December 19, 2022

Exhibit 10.4 INHIBITOR THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into as of December 13, 2022 (the ?Effective Date?), is made by and between Inhibitor Therapeutics, Inc., a Delaware corporation (the ?Company?) and James A. McNulty (?Executive? and, together with the Company, the ?Parties?). WHEREAS, the Company desires to assure itself of the serv

License Agreement by and between the Company and Mayne Pharma, dated December 13, 2022, as filed with Form 8-K, dated December 19, 2022

Exhibit 10.2 Licence Agreement Date Parties Name Mayne Pharma Ventures Pty Ltd, an Australian company ACN 168 896 357 Short form name Mayne Pharma Notice details 1538 Main North Road, Salisbury South, SA 5106 Australia Facsimile: +61 3 9614 7022 Attention: General Counsel Name Inhibitor Therapeutics, Inc., formerly known as Hedgepath Pharmaceuticals, Inc., a company incorporated in Delaware, succe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE HEDGEPATH, LLC, Plaintiff, v. C.A. No. 2019-0529-JTL BRENDAN MAGRAB, STEFAN J. CROSS, DR. R. DANA ONO, ROBERT D. MARTIN, W. MARK WATSON, NICHOLAS J. VIRCA and MAYNE PHARMA VENTURES PTY LTD., Defendant

Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE HEDGEPATH, LLC, Plaintiff, v. C.A. No. 2019-0529-JTL BRENDAN MAGRAB, STEFAN J. CROSS, DR. R. DANA ONO, ROBERT D. MARTIN, W. MARK WATSON, NICHOLAS J. VIRCA and MAYNE PHARMA VENTURES PTY LTD., Defendants, and HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation, Nominal Defendant. SAMUEL SEARS, Individually And On Behalf of All Others

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 (September 9, 2022) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisd

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 (June 1, 2022) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-1

Letter Agreement to Amend Term Debt Facility, dated March 9, 2022, between the Company and Mayne Pharma *.

Exhibit 10.13 1 March 2022 Mark Watson Inhibitor Therapeutics [email protected] Dear Mark Second Loan Amendment Mayne Pharma Ventures Pty Ltd (Mayne Pharma) is offering to amend the loan outlined in our letter signed 12 December 2020, as amended on 10 January 2022 (Loan) to provide a loan to Inhibitor Therapeutics, Inc. (INTI), as set out below. Line Amount: The Facility Limit is increased by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor T

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 (January 13, 2022) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdict

Letter Agreement to Amend Term Debt Facility, dated January 13, 2022, between the Company and Mayne Pharma.

Exhibit 10.1 10 January 2022 Mark Watson Inhibitor Therapeutics Dear Mark Loan Amendment Mayne Pharma Ventures Pty Ltd (Mayne Pharma) is offering to amend the loan outlined in our letter signed 12 December 2020 (Loan) to provide a loan to Inhibitor Therapeutics, Inc. (INTI), as set out below. Line Amount: The Facility Limit is increased by USD50,000 to USD281,000. Availability: The USD50,000 incre

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-1

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor T

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 d64046d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 (December 31, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (

Letter Agreement for Term Debt Facility, dated December 12, 2020, between the Company and Mayne Pharma.

EX-10.1 Exhibit 10.1 12 December 2020 Mark Watson, Dana Ono and Debra Peattie Inhibitor Therapeutics, Inc. Special Committee [email protected] Dear INTI Special Committee Loan offer Mayne Pharma Ventures Pty Ltd (Mayne Pharma) offers a loan to Inhibitor Therapeutics, Inc. (INTI) from 14 December 2020 in USD up to the Facility Limit for Purpose (both as defined below) as set out in this letter.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K 1 d64746d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 (December 12, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665

Quarterly Report - FORM 10-Q

10-Q 1 d24961d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 d33676d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 (September 17, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-07936

Quarterly Report - 10-Q

10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 (June 28, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdictio

Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 (June 4, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction

Promissory Note, dated May 2, 2020, by and between the Company and Citibank, N.A.

EX-10.1 Exhibit 10.1 DocuSign Envelope ID: E25578FB-4593-FFC1-9237-059352B386FA U.S. Small Business Administration PAYCHECK PROTECTION PROGRAM LOAN NOTE SBA Loan# PLP# 37765472-00 SBA Loan Name INHIBITOR THERAPEUTICS, INC. Date 05/02/2020 Loan Amount $41,600.00 Interest Rate 1.00% Borrower INHIBITOR THERAPEUTICS, INC. Lender Citibank, N.A. Maturity Date 5/2/2022 1. PROMISE TO PAY: In return for th

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K 1 d187824d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 (May 3, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or

Quarterly Report - 10-Q

10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 (April 10, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdict

INTI / Inhibitor Therapeutics, Inc. 10-K - Annual Report - 10-K

10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2019 Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of incorpo

INTI / Inhibitor Therapeutics, Inc. DEF 14C - - DEF 14C

DEF 14C 1 d809223ddef14c.htm DEF 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of t

Sublicense Agreement, dated August 27, 2019, by and between Mayne Pharma International Pty Ltd and the Company (16) +

EX-10.1 Exhibit 10.1 Redactions with respect to certain portions hereof denoted with “***” Execution Date: August 27, 2019 Effective Date: August 20, 2019 SUBLICENSE AGREEMENT BETWEEN MAYNE PHARMA INTERNATIONAL PTY LTD & INHIBITOR THERAPEUTICS, INC. SUBLICENSE AGREEMENT THIS SUBLICENSE AGREEMENT (this “Agreement”) is executed on August 27, 2019 and entered into effective as of August 20, 2019 by a

INTI / Inhibitor Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q

10-Q 1 d787025d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from

INHIBITOR Therapeutics Appoints Dr. Debra Peattie to its Board of Directors Industry Veteran Brings 30 Years of Experience to Support INTI’s Biopharmaceutical and Corporate Programs

EX-99.1 Exhibit 99.1 INHIBITOR Therapeutics Appoints Dr. Debra Peattie to its Board of Directors Industry Veteran Brings 30 Years of Experience to Support INTI’s Biopharmaceutical and Corporate Programs Tampa, Fla. — October 31, 2019 — INHIBITOR Therapeutics, Inc. (OTCQB:INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inh

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

8-K 1 d625780d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 (October 30, 2019) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2019 (August 21, 2019) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdi

HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to “INTI” Effective August 20, 2019 New Corporate Brand Exemplifies Multiple Near-term Growth Opportunities Involving Lead Technology, SUBA™- Itr

EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to “INTI” Effective August 20, 2019 New Corporate Brand Exemplifies Multiple Near-term Growth Opportunities Involving Lead Technology, SUBA™- Itraconazole, Inhibiting the Hedgehog Signaling Pathway INHIBITOR to Hold End of Phase 2 Meeting with FDA in Q4 2019 Prior to Filing

Certificate of Amendment to the Company’s Certificate of Incorporation, dated August 20, 2019 (14)

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HEDGEPATH PHARMACEUTICALS, INC. The undersigned, for the purposes of amending the Certificate of Incorporation of HedgePath Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRS

Cautionary Note on Forward-Looking Statements and Disclaimers This presentation includes or incorporates by reference statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws. These statements rel

EX-99.2 Corporate Presentation August 2019 OTCQB:INTI Exhibit 99.2 Cautionary Note on Forward-Looking Statements and Disclaimers This presentation includes or incorporates by reference statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws. These statements relate to future events or to our future performance, and involve significant known an

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

8-K 1 d793055d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2019 (August 19, 2019) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (S

HPPI / HedgePath Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q

10-Q 1 d747883d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C

Regulation FD Disclosure, Other Events

8-K 1 d767489d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2019 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jur

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 d774368d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2019 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jur

Other Events

8-K 1 d756566d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2019 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jur

HPPI / HedgePath Pharmaceuticals, Inc. DEF 14C - - DEF 14C

DEF 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☒ Definitive Information Statement ☐ Confidential, for Us

HPPI / HedgePath Pharmaceuticals, Inc. PRE 14C - - PRE 14C

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Definitive Information Statement ☐ Confidential, for Use of the

HPPI / HedgePath Pharmaceuticals, Inc. 10-Q Quarterly Report FORM 10-Q

10-Q 1 d709188d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro

HPPI / HedgePath Pharmaceuticals, Inc. POS AM POS AM

POS AM Table of Contents As filed with the Securities and Exchange Commission on April 26, 2019 Registration No.

W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals

EX-99.1 Exhibit 99.1 W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals Tampa, FL, April 15, 2019 – HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a pharmaceutical development company focused on discovering, developing and ultimately commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders, announced today that HedgePath’s Bo

Financial Statements and Exhibits, Other Events

8-K 1 d696673d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2019 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other ju

HPPI / HedgePath Pharmaceuticals, Inc.

begin 644 filename1 M)5!$1BTQ+C8-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5AF4@,C4O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F *!!(,?D""L1'$G0WP !!@#U MH@?K#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @ M(" @(" @#0HR-" P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X.

Amended and Restated Sublicense Agreement, dated December 17, 2018, by and among Mayne Pharma, Mayne Pharma International and the Company (15) +

EX-10.6 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Exhibit 10.6 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” December 17, 2018 AMENDED AND RESTATED SUBLICENSE AGREEMENT BETWEEN MAYNE PHARMA INTERNATIONAL PTY LTD & HEDGEPATH PHARMACEUTICALS

HPPI / HedgePath Pharmaceuticals, Inc. FORM 10-K (Annual Report)

10-K 1 d668655d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Third Amended and Restated Supply and License Agreement, dated December 17, 2018, by and among Mayne Pharma, Mayne Pharma International and the Company (15) +

EX-10.5 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Exhibit 10.5 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” Third Amended and Restated Supply and License Agreement Mayne Pharma Ventures Pty Ltd (Mayne Pharma) HedgePath Pharmaceuticals, In

Agreement, dated December 17, 2018, by and among Mayne Pharma, Mayne Pharma International and the Company (15)

EX-10.7 Exhibit 10.7 AGREEMENT This AGREEMENT (this “Agreement”) is entered into by and among HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation (“HPPI”), MAYNE PHARMA VENTURES PTY LTD, an Australian company ACN 168 896 357 (“Mayne Pharma”), and MAYNE PHARMA INTERNATIONAL PTY LTD, an Australian company ACN 007 870 984 (“Mayne Pharma International” and together with Mayne Pharma, collectively,

Regulation FD Disclosure, Other Events

8-K 1 d705755d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2019 (February 11, 2019) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 3

Amended and Restated Certificate of Designation of Series B Preferred Stock of the Company, dated February 1, 2019 (6)

DEF 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permit

Employment Letter Agreement, dated December 31, 2018, between the Company and Garrison J. Hasara (12)

Exhibit 10.2 CONFIDENTIAL VIA EMAIL December 31 2018 Garrison J. Hasara, CPA c/o HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Re: Terms of Employment Dear Garry: HedgePath Pharmaceuticals, Inc. (the “Company”) hereby extends to you an offer to continue your employment with the Company under the revised employment terms as set forth below. This letter is r

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 d672710d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2018 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or

Employment Letter Agreement, dated December 31, 2018, between the Company and Nicholas J. Virca (12)

EX-10.1 2 d672710dex101.htm EX-10.1 Exhibit 10.1 CONFIDENTIAL VIA EMAIL December 31, 2018 Mr. Nicholas J. Virca c/o HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Re: Terms of Employment Dear Nick: HedgePath Pharmaceuticals, Inc. (the “Company”) hereby extends to you an offer to continue your employment with the Company under the revised employment terms as

HPPI / HedgePath Pharmaceuticals, Inc. PRE 14C

PRE 14C 1 d679573dpre14c.htm PRE 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of t

HPPI / HedgePath Pharmaceuticals, Inc. DEF 14C

DEF 14C 1 d678464ddef14c.htm DEF 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of t

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SC 13D/A Activist Investment

SC 13D/A 1 tv509463sc13d-a.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd 1538 Main North Road, Salisbur

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 10 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: December 18, 2018 Mayne Pharma Ventures Pty Ltd /s/ Nick Freeman Nick Freeman, Company Sec

HedgePath Pharmaceuticals and Mayne Pharma Enter into Updated Collaboration and Funding Agreements HPPI to transfer SUBA-Itraconazole BCCNS clinical program to Mayne Pharma in consideration of up to $5 million in new funding from Mayne Pharma and a 9

EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals and Mayne Pharma Enter into Updated Collaboration and Funding Agreements HPPI to transfer SUBA-Itraconazole BCCNS clinical program to Mayne Pharma in consideration of up to $5 million in new funding from Mayne Pharma and a 9% royalty on future SUBA-Itraconazole BCCNS sales in the U.S. With new funding, HPPI to move towards IND filing during 2019 and r

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2018 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of inco

HPPI / HedgePath Pharmaceuticals, Inc. 10-Q (Quarterly Report)

10-Q 1 d613945d10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil

Regulation FD Disclosure

8-K 1 d650579d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2018 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other

JOINT FILING AGREEMENT

EX-99.1 2 tv506195ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 9 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: November 5, 2018 Mayne Pharma Ventures Pty Ltd /s

MAYNE PHARMA VENTURES PTY LTD 1528 Main north road salisbury south 5106 SA

Exhibit 99.2 MAYNE PHARMA VENTURES PTY LTD 1528 Main north road salisbury south 5106 SA Australia November 2, 2018 VIA E-MAIL HedgePath Pharmaceuticals, Inc. 324 South Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Attention: · Dana Ono [email protected] · Bob Martin [email protected] · Mark Watson [email protected] Copy to: · Lawrence A. Rosenbloom, Ellenoff Grossman & Schole LLP, lr

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd 1538 Main North Road, Salisbury South 5106 SA, Australia 61 3 8614 7711

HPPI / HedgePath Pharmaceuticals, Inc. FORM 10-Q (Quarterly Report)

10-Q 1 d557556d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from

HedgePath Pharmaceuticals Closes Second Tranche of Mayne Pharma Financing Additional $1.6 million in preferred stock and warrant funding to support SUBA BCCNS regulatory program HPPI to meet with FDA this month to discuss proposed 2018 NDA filing

EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals Closes Second Tranche of Mayne Pharma Financing Additional $1.6 million in preferred stock and warrant funding to support SUBA BCCNS regulatory program HPPI to meet with FDA this month to discuss proposed 2018 NDA filing TAMPA, Fla., July 9, 2018 /PRNewswire/ — HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company th

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2018 (July 6, 2018) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdict

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd 1538 Main North Road, Salisbury South 5106 SA, Australia 61 3 8614 7711

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 8 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: July 6, 2018 Mayne Pharma Ventures Pty Ltd /s/ Nick Freeman Nick Freeman, Company Secretary

HPPI / HedgePath Pharmaceuticals, Inc. 10-Q (Quarterly Report)

10-Q 1 d558032d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to

HPPI / HedgePath Pharmaceuticals, Inc. POS AM

POS AM Table of Contents As filed with the Securities and Exchange Commission on April 4, 2018 Registration No.

HPPI / HedgePath Pharmaceuticals, Inc. FORM 10-K (Annual Report)

Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

HPPI / HedgePath Pharmaceuticals, Inc. RDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 22, 2018 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 HedgePath Pharmaceuticals, Inc.

Amendment No. 2 to Second Amended and Restated Supply and License Agreement and Amendment No. 1 to Sublicense Agreement, dated January 10, 2018, by and among Mayne Pharma, Mayne Pharma International and the Company (13)+

EX-10.2 6 d523601dex102.htm EX-10.2 Exhibit 10.2 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** NOTE: CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO CERTAIN PORTIONS HEREOF DENOTED WITH “[***]” AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT AND AMENDMENT NO. 1 TO SUBLICENSE AGREE

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

8-K 1 d523601d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2018 (January 8, 2018) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-079366

HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs HPPI receives three tranche preferred stock and warrant funding, with $2.4 million upfront, $1.6 million by mid-2018, and an ad

EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs HPPI receives three tranche preferred stock and warrant funding, with $2.4 million upfront, $1.6 million by mid-2018, and an additional $1 million by year end if BCCNS NDA is accepted HPPI?s Supply and License Agreement with Mayne Pharma amended to remove

Securities Purchase Agreement, dated January 8, 2018, between the Company and Mayne Pharma (9)

EX-10.1 5 d523601dex101.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT Dated January 8, 2018 by and between HEDGEPATH PHARMACEUTICALS, INC. and MAYNE PHARMA VENTURES PTY LTD EXECUTION VERSION TABLE OF CONTENTS ARTICLE I SALE OF PURCHASED SECURITIES; CLOSING 6 1.1 Sale and Purchase of Purchased Securities 6 1.2 Closings 6 1.3 Use of Proceeds 7 ARTICLE II DEFINITIONS 7 2.1

Form of Warrant issued in the January 2018 Series B Preferred Stock Financing (9)

EX-4.1 Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJEC

Certificate of Correction to the Certificate of Designation of Series B Preferred Stock of the Company, dated January 10, 2018 (13)

EX-3.2 Exhibit 3.2 CERTIFICATE OF CORRECTION OF CERTIFICATE OF DESIGNATION, OF SERIES B CONVERTIBLE PREFERRED STOCK OF HEDGEPATH PHARMACEUTICALS, INC. HedgePath Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY THAT: 1. The name of the corporation is HedgePath Pharmaceutic

Certificate of Designation of Series B Preferred Stock of the Company, dated January 8, 2018 (13)

EX-3.1 2 d523601dex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK OF HEDGEPATH PHARMACEUTICALS, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware (the “DGCL”), the undersigned officer of HedgePath Pharmaceuticals, Inc., a corporation organized and e

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd 1538 Main North Road, Salisbury South 5106 SA, Australia 61 3 8614 7711

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 7 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: January 11, 2018 Mayne Pharma Ventures Pty Ltd /s/ Nick Freeman Nick Freeman, Company Secre

Submission of Matters to a Vote of Security Holders

8-K 1 d473651d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2017 (December 18, 2017) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-079

HPPI / HedgePath Pharmaceuticals, Inc. DEF 14A

DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240.

HedgePath Pharmaceuticals 10-Q (Quarterly Report)

10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Cautionary Note on Forward-Looking Statements; No Offer of Securities This presentation includes or incorporates by reference statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws. These statem

EX-99.1 exploring new pathways to cancer therapy HedgePath Pharmaceuticals, Inc. 1 ? 2017 HedgePath Pharmaceuticals, Inc. All rights reserved Exhibit 99.1 Cautionary Note on Forward-Looking Statements; No Offer of Securities This presentation includes or incorporates by reference statements that constitute ?forward-looking statements? within the meaning of the U.S. federal securities laws. These s

Financial Statements and Exhibits, Other Events

8-K 1 d465248d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2017 (October 5, 2017) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-07

HedgePath Pharmaceuticals 10-Q (Quarterly Report)

10-Q 1 d313404d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C

HPPI / HedgePath Pharmaceuticals, Inc. / Hedgepath, Llc - SC 13D/A Activist Investment

SC 13D/A 1 d410505dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Nicholas J. Virca President 324 South Hyde Park Avenue, Suite 350 Tampa, FL

JOINT FILING AGREEMENT

EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned does hereby consent and agree to the joint filing on behalf of each of them of this Schedule 13D, and to the inclusion of this Joint Filing Agreement as an exhibit thereto. Dated: March 17, 2016 HEDGEPATH, LLC By: /s/ James A. McNulty Name: Jam

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2017 (July 25, 2017) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jur

HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission HPPI to proceed with streamlined 505(b)(2) regulatory pathway for SUBA™-Itraconazole as a treatment for Basal Cell Carcinoma Nevus Syndrome FDA p

EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission HPPI to proceed with streamlined 505(b)(2) regulatory pathway for SUBA?-Itraconazole as a treatment for Basal Cell Carcinoma Nevus Syndrome FDA provides written guidance on data from HPPI?s ongoing clinicial trial and the data requirements for NDA filing and potential FDA a

HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update 35 subjects with Basal Cell Carcinoma Nevus Syndrome in ongoing Phase 2(b) trial have a median time on study of 32 weeks of dosi

EX-99.1 2 d514186dex991.htm PRESS RELEASE Exhibit 99.1 HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update 35 subjects with Basal Cell Carcinoma Nevus Syndrome in ongoing Phase 2(b) trial have a median time on study of 32 weeks of dosing with SUBA™-Itraconazole Third interim analysis shows 97% of patients avoiding surgery with 3

Financial Statements and Exhibits, Other Events

8-K 1 d514186d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2017 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other

HedgePath Pharmaceuticals FORM 10-Q (Quarterly Report)

10-Q 1 d372685d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro

As filed with the Securities and Exchange Commission on April 21, 2017

POS AM 1 d345769dposam.htm POST - EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on April 21, 2017 Registration No. 333-212092 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact n

Amendment No. 1 to Second Amended and Restated Supply and License Agreement, dated November 22, 2016, by and among the Company and Mayne Pharma (14)

Amendment No. 1 to Second Amended and Restated Supply and License Agrrement Exhibit 10.16 AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT (the “Amendment”), dated effective as of November 22, 2016 (the “Effective Date”), is by and among: (i) MAYNE PHARMA VENTURES PTY LTD, an Australian comp

Second Amendment to Employment Agreement, dated February 16, 2017, between the Company and Nicholas J. Virca (14)

2nd Amendment to Employment Agreement between the Company and Nicholas J. Virca Exhibit 10.6 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), is dated and effective as of February 16, 2017 by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Nicholas J. Virca (the “Executive”). The Company and the Execu

First Amendment to Employment Agreement, dated February 16, 2017, between the Company and Garrison J. Hasara (14)

EX-10.11 3 d306040dex1011.htm 1ST AMENDMENT TO EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND GARRISON J. HASARA Exhibit 10.11 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), is dated and effective as of February 16, 2017 by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Garrison J. Hasara (the “Executi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Regulation FD Disclosure

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2017 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of

HedgePath Pharmaceuticals DEFINITIVE INFORMATION STATEMENT

Definitive Information Statement SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

8-K 1 d306035d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2016 (November 30, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 6 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: December 1, 2016 Mayne Pharma Ventures Pty Ltd /s/ Mark Cansdale Mark Cansdale, Company Sec

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SC 13D/A Activist Investment

SC 13D/A 1 v454243sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd Level 1, 99 King Street Melbourne

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2016 (November 22, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd Level 1, 99 King Street Melbourne, Victoria 3000 Australia 61 3 8614 77

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 5 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: November 28, 2016 Mayne Pharma Ventures Pty Ltd /s/ Mark Cansdale Mark Cansdale, Company Se

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SC 13D/A Activist Investment

SC 13D/A 1 v453180sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd Level 1, 99 King Street Melbourne

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 4 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: November 15, 2016 Mayne Pharma Ventures Pty Ltd /s/ Mark Cansdale Mark Cansdale, Company Se

Changes in Control of Registrant

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2016 (November 2, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or oth

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 3 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: November 7, 2016 Mayne Pharma Ventures Pty Ltd /s/ Mark Cansdale Mark Cansdale, Company Sec

EX-99.5

EX-99.5 3 v452300ex99-5.htm EXHIBIT 99.5 Exhibit 99.5

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SC 13D/A Activist Investment

SC 13D/A 1 v452300sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd Level 1, 99 King Street Melbourne

HedgePath Pharmaceuticals FORM 10-Q (Quarterly Report)

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

HedgePath Pharmaceuticals FORM S-8

Form S-8 Table of Contents As filed with the Securities and Exchange Commission on October 24, 2016 Registration No.

HEDGEPATH PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN

EX-99.1 4 d269036dex991.htm HEDGEPATH PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN Exhibit 99.1 HEDGEPATH PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the HedgePath Pharmaceuticals, Inc. 2014 Equity Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, offic

HedgePath Pharmaceuticals FROM 10-Q (Quarterly Report)

From 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

85,296,000 Shares of Common Stock

Final Prospectus Table of Contents Filed pursuant to Rule 424(b)(3) Registration No.

HedgePath Pharmaceuticals AMENDMENT NO. 2 TO FORM S-1

Amendment No. 2 to Form S-1 As filed with the Securities and Exchange Commission on July 20, 2016 Registration No. 333-212092 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 30-0793665 (State

HedgePath Pharmaceuticals ESP

CORRESP 1 filename1.htm HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 July 21, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: John Reynolds Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-212092 Dear Mr. Reynolds: Pursuant to Ru

HedgePath Pharmaceuticals AMENDMENT NO. 1 TO FORM S-1

S-1/A 1 d228665ds1a.htm AMENDMENT NO. 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on July 18, 2016 Registration No. 333-212092 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in it

HedgePath Pharmaceuticals ESP

SEC Response Letter 1345 AVENUE OF THE AMERICAS, 11th FLOOR NEW YORK, NEW YORK 10105 TELEPHONE: (212) 370-1300 FACSIMILE: (212) 370-7889 www.

LETTER

Mail Stop 3561 July 6, 2016 Via E-mail Nicholas J. Virca President and Chief Executive Officer HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 17, 2016 File No. 333-212092 Dear Mr. Virca: We have limited our review of your registration statement to those issues we have addressed

As filed with the Securities and Exchange Commission on June 17, 2016

S-1 1 d210299ds1.htm FORM S-1 REGISTRATION STATEMENT Table of Contents As filed with the Securities and Exchange Commission on June 17, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SCHEDULE 13D (AMENDMENT NO. 2) Activist Investment

SC 13D/A 1 t1600395sc13da.htm SCHEDULE 13D (AMENDMENT NO. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Level 1, 99 King Street Melbourne, Victo

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2016 (May 25, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other juris

Certificate of Amendment to the Company’s Certificate of Incorporation (5)

Certificate of Amendment Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HEDGEPATH PHARMACEUTICALS, INC. HedgePath Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: First: That the Board of Directors of the Corporatio

HedgePath Pharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2016 (May 20, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other juris

HedgePath Pharmaceuticals FORM 10-Q (Quarterly Report)

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

HedgePath Pharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2016 (May 3, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other juri

HedgePath Pharmaceuticals DEFINITIVE INFORMATION STATEMENT

DEF 14C 1 d176923ddef14c.htm DEFINITIVE INFORMATION STATEMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Check the appropriate box: ¨ Preliminary Information Statement x Definitive Information Statement ¨ Confidential, for Use of the Commission Only (as perm

Form of Warrant issued in the 2016 Private Placement (8)

Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, T

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2016 (April 11, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other j

Form of Securities Purchase Agreement issued in the 2016 Private Placement (10)

Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is dated as of , 2016, between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto, whether such purchaser is or becomes a signature as of the Initial Closing or any Subsequent Closing

HedgePath Pharmaceuticals PRELIMINARY INFORMATION STATEMENT

PRE 14C 1 d176923dpre14c.htm PRELIMINARY INFORMATION STATEMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Check the appropriate box: x Preliminary Information Statement ¨ Definitive Information Statement ¨ Confidential, for Use of the Commission Only (as per

HedgePath Pharmaceuticals REQUEST FOR WITHDRAWAL

RW 1 d68758drw.htm REQUEST FOR WITHDRAWAL HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 March 22, 2016 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attention: Ruairi J. Regan, Esq. Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333

COMMON STOCK PURCHASE WARRANT HEDGEPATH PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2016

EX-4.4 2 d68758dex44.htm FORM OF WARRANT Exhibit 4.4 COMMON STOCK PURCHASE WARRANT HEDGEPATH PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2016 This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af

As filed with the Securities and Exchange Commission on February 23, 2016

S-1/A 1 d68758ds1a.htm AMENDMENT NO 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on February 23, 2016 Registration No. 333-208594 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in

SECURITIES PURCHASE AGREEMENT

Form of Subscription Agreement Exhibit 10.21 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of , 2016, between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto, whether such purchaser is or becomes a signature as of the Initial Closing or any Subsequent Closing (each

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

10-K 1 d113219d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Amendment No. 1 to Amended and Restated Equity Holders Agreement, dated December 17, 2015, Company, Mayne Pharma Ventures Pty Ltd., Hedgepath, LLC., Nicholas J. Virca and Frank O’Donnell (11)

EX-10.1 2 d100976dex101.htm AMENDMENT NO. 1 TO AMENDED AND RESTATED EQUITY HOLDERS AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT (the “Amendment”), dated effective as of December 17, 2015 (the “Effective Date”), is by and among: (i) MAYNE PHARMA VENTURES PTY LTD, an Australian company

HedgePath Pharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2015 (December 17, 2015) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o

HedgePath Pharmaceuticals FORM S-1

S-1 1 d68758ds1.htm FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on December 17, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 30-0793665 (State o

HedgePath Pharmaceuticals RDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION November 13, 2015 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 HedgePath Pharmaceuticals, Inc.

HedgePath Pharmaceuticals RDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION November 13, 2015 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Hedgepath Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 d18401d10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file

Sublicense Agreement, entered into effective as of September 2, 2015, by and between Mayne Pharma International Pty Ltd and the Company. (8)+

EX-10.1 2 d85970dex101.htm SUBLICENSE AGREEMENT Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Exhibit 10.1 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” September 2, 2015 SUBLICENSE AGREEMENT BETWEEN MAYNE PHARMA INTERNATIONAL PTY LTD & HEDGEP

HedgePath Pharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2015 (September 2, 2015) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o

Second Amended and Restated Supply and License Agreement, dated May 15, 2015, by and among the Company and Mayne Pharma. (7)+

EX-10.4 6 d938337dex104.htm SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT Exhibit 10.4 FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” Final Date: May 15, 2015 Second Amended and Rest

Master Clinical Services Agreement, dated June 15, 2015, by and between the Company and SciQuus, Inc. (10)+

Exhibit 10.6 FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with ?***? MASTER CLINICAL SERVICES AGREEMENT This Master Clinical Services Agreement (this ?Agreement?) is executed as of 15 June, 2015 and mad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 d938337d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from

HEDGEPATH PHARMACEUTICALS, INC. Common Stock Purchase Warrant

EX-4.1 2 d938337dex41.htm WARRANT Exhibit 4.1 EXECUTION VERSION THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE E

FIRST AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENT

Exhibit 10.2 EXECUTION VERSION FIRST AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENT THIS FIRST AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENT (the ?Amendment?), is dated as of May 15, 2015, by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Frank E. O?Donnell, Jr., M.D. (the ?Executive Chairman?). The Company and the Executive Chairman are referred to collectively he

Securities Purchase Agreement, dated May 15, 2015, by and between the Company and Mayne Pharma Ventures Pty Ltd. (7)

EX-10.5 7 d938337dex105.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.5 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT Dated May 15, 2015 by and between HEDGEPATH PHARMACEUTICALS, INC. and MAYNE PHARMA VENTURES PTY LTD TABLE OF CONTENTS Page ARTICLE I SALE AND PURCHASE OF PURCHASED SECURITIES; CLOSING 2 1.1 Sale and Purchase of Purchased Securities 2 1.2 Closing 2 ARTICLE II DEFINITIONS 3 2.1 Defi

First Amendment to Employment Agreement, dated May 15, 2015, between the Company and Nicholas J. Virca (7)

EX-10.3 5 d938337dex103.htm FIRST AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.3 EXECUTION VERSION FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), is dated as of May 15, 2015 by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Nicholas J. Virca (the “Executive”). The Company and the Executive are referr

Amended and Restated Equity Holders Agreement, dated May 15, 2015, by and between the Company, Mayne Pharma Ventures Pty Ltd., Hedgepath, LLC, Nicholas J. Virca and Frank O’Donnell, Jr. M.D. (10)+

EX-10.1 3 d938337dex101.htm AMENDED AND RESTATED EQUITY HOLDERS AGREEMENT Exhibit 10.1 EXECUTION VERSION HEDGEPATH PHARMACEUTICALS, INC. AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT Dated As of May 15, 2015 HEDGEPATH PHARMACEUTICALS, INC. AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT This AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT (this “Agreement”) is made and entered into as of the 15th d

30,600,000 Shares Common Stock

424B3 1 d783002d424b3.htm 424B(3) Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-198800 Prospectus 30,600,000 Shares Common Stock This prospectus relates to the offer for sale of up to a potential aggregate of 30,600,000 shares of common stock, par value $0.0001 per share, of HedgePath Pharmaceuticals, Inc. by the selling stockholders named herein. We are not offering any

HedgePath Pharmaceuticals ESP

CORRESP 1 filename1.htm HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 August 6, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey P. Riedler Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-198800 Dear Mr. Riedler: Pursuant

Certificate of Amendment to the Company’s Certificate of Incorporation (3)

Certificate of Amendment EXHIBIT 3.3 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HEDGEPATH PHARMACEUTICALS, INC. HedgePath Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: First: That the Board of Directors of the Corporatio

As filed with the Securities and Exchange Commission on July 22, 2015

S-1/A 1 d783002ds1a.htm AMENDMENT NO 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on July 22, 2015 Registration No. 333-198800 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its

HedgePath Pharmaceuticals DEFINITIVE INFORMATION STATEMENT

Definitive Information Statement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

HedgePath Pharmaceuticals PRELIMINARY INFORMATION STATEMENT

PRE 14C 1 d935591dpre14c.htm PRELIMINARY INFORMATION STATEMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨

HPPI / HedgePath Pharmaceuticals, Inc. / Mayne Pharma Ventures Pty Ltd - SCHEDULE 13D (AMENDMENT NO. 1) Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Level 14, 474 Flinders Street Melbourne, Victoria 3000 Australia 61 3 8614 7711 (Name, Address and Te

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 d932170d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2015 (May 15, 2015) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665

Second Amended and Restated Bylaws of the Company (4)

Second Amended and Restated ByLaws Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF HEDGEPATH PHARMACEUTICALS, INC. (a Delaware Corporation) (adopted effective as of May 15, 2015) ARTICLE 1 OFFICES SECTION 1.1. Principal Office. The principal offices of the HedgePath Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?) shall be in such location as the Board of Directors of the Corpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-1

Code of Ethical Conduct (13)

Exhibit 14 HEDGEPATH PHARMACEUTICALS, INC. CODE OF ETHICAL CONDUCT Preface The honesty, integrity, ethics, respect for others and sound judgment displayed by directors, principal executives and financial officers of HedgePath Pharmaceuticals, Inc. (?HPPI?) set the tone for business conduct, and are fundamental to the proper functioning, reputation and success of HPPI. This Code of Ethical Conduct

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

10-K 1 d831773d10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file

INTI / Inhibitor Therapeutics, Inc. CT ORDER - -

begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.%P94P`C$+`P<#%LP(#`@-C$R(#7!E+T]B:E-T;3X^<2)5"%! MVW23!D-U$Y"?/""!Y'R0(FKT7\7YM7$>VT5I:YYIYCWW.Y!Q8!!29!)L!B M8,*&!(3DP"G(.`+.

2014 Equity Incentive Plan (included as Annex B to the Registrant’s Definitive Information Statement filed on October 13, 2014)

DEF 14C 1 d798287ddef14c.htm DEFINITIVE INFORMATION STATEMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 d772477d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period

INTI / Inhibitor Therapeutics, Inc. PRE 14C - - PRELIMINARY INFORMATION STATEMENT

Preliminary Information Statement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

LETTER

September 26, 2014 Via E-mail Nicholas J. Virca President and Chief Executive Officer HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed September 17, 2014 File No. 333-198800 Dear Mr. Virca: We have limited our review of your registration statement to the resolution of your pending co

INTI / Inhibitor Therapeutics, Inc. S-1 - Registration Statement - FORM S-1

S-1 1 d783002ds1.htm FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on September 17, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 30-0793665 (State

Employment Agreement, dated September 4, 2014, between the Company and Garrison J. Hasara (4)

Employment Agreement, dated September 4, 2014, with Garrison J. Hasara Exhibit 10.1 FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain porti

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2014 (September 4, 2014) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o

INTI / Inhibitor Therapeutics, Inc. CT ORDER - -

begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0T(#`@;V)J#3P\+TQI;F5AF4@-3')E9@T*,`T*)25%3T8-"B`@("`@ M("`@#0HU-B`P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF``*>]PRH@)$! M),O1@"S&`L4,##<8N!DXOZ>P+(`JE?L-H9DJD!4;+H.(,BH#!!@`8*0'<@T* M96YD7!E+U!A9V4^/@UE;F1O8FH-#<@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9I<&4O3V)J4W1M/CYS M=')E86T-"FC>U%7=:]LP$/]7]+@]%'U8LFPHA29;6&$KHPGKH/3!2TQB2.QB MNVS][W=WMF3%3=(M+V,/%

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13

AMENDED AND RESTATED BYLAWS OF HEDGEPATH PHARMACEUTICALS, INC. (a Delaware Corporation) (adopted effective as of July 18, 2014) ARTICLE 1

EX-3.1 2 d762792dex31.htm AMENDED AND RESTATED BYLAWS OF THE COMPANY Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF HEDGEPATH PHARMACEUTICALS, INC. (a Delaware Corporation) (adopted effective as of July 18, 2014) ARTICLE 1 OFFICES SECTION 1.1. Principal Office. The principal offices of the HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”) shall be in such location as the Boar

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

8-K 1 d762792d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2014 (July 18, 2014) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-079366

INTI / Inhibitor Therapeutics, Inc. / ODONNELL FRANCIS E JR - SCHEDULE 13D AMENDMENT NO. 1 Activist Investment

Schedule 13D Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Nicholas J. Virca President 324 South Hyde Park Avenue, Suite 350 Tampa, FL 33606 (81

INTI / Inhibitor Therapeutics, Inc. / Mayne Pharma Ventures Pty Ltd - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Level 14, 474 Flinders Street Melbourne, Victoria 3000 Australia 61 3 8614 7711 (Name, Address and Telep

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D jointly on behalf of each such party. Date: July 7, 2014 MAYNE PHARMA VENTURES

Employment Agreement, dated June 24, 2014, between the Company and Nicholas J. Virca (3)+

EX-10.6 9 d750157dex106.htm EMPLOYMENT AGREEMENT Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” Exhibit 10.6 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “**

EXECUTIVE CHAIRMAN AGREEMENT

Executive Chairman Agreement Exhibit 10.7 EXECUTIVE CHAIRMAN AGREEMENT THIS EXECUTIVE CHAIRMAN AGREEMENT (the “Agreement”) is made as of the 24th day of June, 2014 (the “Effective Date”) and is by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Frank E. O’Donnell. Jr., M.D. (the “Executive Chairman”). WHEREAS, the Executive Chairman is presently serving in

SECURITIES PURCHASE AGREEMENT Dated June 24, 2014 by and between HEDGEPATH PHARMACEUTICALS, INC. MAYNE PHARMA VENTURES PTY LTD TABLE OF CONTENTS Page ARTICLE I SALE OF PURCHASED SECURITIES; CLOSING 2 1.1 Purchase 2 1.2 Closing 2 ARTICLE II DEFINITION

EX-10.1 4 d750157dex101.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT Dated June 24, 2014 by and between HEDGEPATH PHARMACEUTICALS, INC. and MAYNE PHARMA VENTURES PTY LTD TABLE OF CONTENTS Page ARTICLE I SALE OF PURCHASED SECURITIES; CLOSING 2 1.1 Purchase 2 1.2 Closing 2 ARTICLE II DEFINITIONS 2 2.1 Definitions 2 ARTICLE III REPRESENTATIONS AND WARRANTIES 7 3.1 Repr

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2014 (June 24, 2014) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdic

PROMISSORY NOTE US$1,250,000.00 Dated as of June 24, 2014

EX-10.3 6 d750157dex103.htm PROMISSORY NOTE Exhibit 10.3 PROMISSORY NOTE US$1,250,000.00 Dated as of June 24, 2014 This PROMISSORY NOTE (this “Note”) is being issued and delivered pursuant to the terms of that certain Stock Purchase Agreement, dated June 24, 2014 (the “Purchase Agreement”), by and between the Maker (as defined below) and the Payee (as defined below). All capitalized terms used but

STOCK PURCHASE AGREEMENT

EX-10.2 5 d750157dex102.htm STOCK PURCHASE AGREEMENT Exhibit 10.2 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of June 24, 2014, is made and entered into by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Hedgepath, LLC, a Florida limited liability company (the “Purchaser”). WHEREAS, the Company desires to raise capita

Warrant, dated June 24, 2014 issued to Hedgepath, LLC, as filed with Form 8-K, dated June 30, 2014

EX-4.1 2 d750157dex41.htm WARRANT Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR

DEBT FORGIVENESS AGREEMENT

Debt Forgiveness Agreement Exhibit 10.5 DEBT FORGIVENESS AGREEMENT THIS DEBT FORGIVENESS AGREEMENT (this “Agreement”) is made and entered into and effective as of this 24th day of June, 2014 by and between HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation (“HPPI”), and HEDGEPATH, LLC a Delaware limited liability company (“HP LLC”). WHEREAS, on the terms and subject to the conditions set fort

Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***”

Amended and Restated Supply and License Agreement Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc.

Warrant, dated June 24, 2014 issued to Hedgepath, LLC (7)

EX-4.2 3 d750157dex42.htm WARRANT Exhibit 4.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR

Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” HEDGEPATH PHARMACEUTICALS, INC. EQUITY HOLDERS

Equity Holders Agreement Exhibit 10.4 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” Exhibit 10.4 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” HEDGEPAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 HedgePath P

- NOTIFICATION OF LATE FILING

NT 10-K 1 d650079dnt10k.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-13467 (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Repor